Companion Diagnostics for Targeted Therapies
From development to commercialization, STAR Health Network provides a novel approach to companion diagnostic partnership
STAR Health Network offers a data-driven approach to companion diagnostic development across our portfolio of assays, leveraging a broad-panel platform used by thousands of oncologists. These assays, including a 648 targeted gene panel, whole transcriptome (RNA), and liquid biopsy, can each incorporate multiple companion diagnostic biomarkers.
STAR Health Network offers a data-driven approach to companion diagnostic development, incorporating multiple biomarker claims within our assays.
STAR HEALTH NETWORK ADVANTAGES
Analytical Performance, Biomarker Refinement, Regulatory Expertise and the Potential to Shorten Time-to-Market
Improve Program Success
As one of the leaders pioneering real-world data, STAR Health Network’ robust clinico-genomics database can be used in tandem with trial sequencing data to set up control arms, compare trial data to real-world data, and generate clinically-meaningful comparator data throughout the trial. STAR Health Network’ sequencing data covers DNA tumor/normal, RNA transcriptome, and key immunotherapy metrics, allowing for a more holistic view to stratify likely responders and refine clinical biomarkers.
STAR Health Network’ robust clinico-genomics database, including 400,000+ clinical-molecular records, can be used in tandem with trial sequencing data to help refine clinical biomarkers and improve program success rates.
STAR Health Network provides an established, validated platform to help reduce development time and costs associated with companion diagnostic development and approval. STAR Health Network’ in-house regulatory affairs team has extensive FDA and industry experience to support our partners through submission.
STAR Health Network’ validated platform, coupled with our in-house FDA and industry experience can help reduce development time and costs associated with companion diagnostic development and approval.
Approved companion diagnostic biomarkers will be incorporated into assays that have been ordered by more than 5,000 oncologists. STAR Health Network can provide a seamless commercialization and reimbursement strategy at launch.
Approved companion diagnostic biomarkers will be incorporated into assays that have already been used by more than 5,000 oncologists. Learn more about our sequencing capabilities.